Wang Baolin, Henao-Tamayo Marcela, Harton Marisa, Ordway Diane, Shanley Crystal, Basaraba Randall J, Orme Ian M
Mycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA.
Clin Vaccine Immunol. 2007 Jul;14(7):902-6. doi: 10.1128/CVI.00077-07.
A fusion protein designated CSU-F36 was constructed that consisted of acylated Rv1411, a potent Toll-like receptor-2 agonist, fused to ESAT-6, a well-characterized immunogenic protein from Mycobacterium tuberculosis. The CSU-F36 fusion protein strongly induced interleukin 12 secretion from macrophages and induced the increased accumulation of CD4 T cells capable of secreting gamma interferon in the lungs of infected mice. These mice were significantly protected from low-dose aerosol challenge with M. tuberculosis, even with CSU-F36 delivered in a simple depot material. This "natural adjuvant"-containing system could potentially bypass the need for more expensive TH1-inducing adjuvants and could be applied to many mycobacterial proteins to provide effective and cheap new vaccines against tuberculosis.
构建了一种名为CSU-F36的融合蛋白，它由酰化的Rv1411（一种有效的Toll样受体2激动剂）与ESAT-6（一种来自结核分枝杆菌的特征明确的免疫原性蛋白）融合而成。CSU-F36融合蛋白强烈诱导巨噬细胞分泌白细胞介素12，并诱导感染小鼠肺部能够分泌γ干扰素的CD4 T细胞积累增加。这些小鼠在接受低剂量结核分枝杆菌气溶胶攻击时得到了显著保护，即使CSU-F36是通过一种简单的长效材料递送的。这种含有“天然佐剂”的系统可能无需使用更昂贵的TH1诱导佐剂，并且可应用于多种分枝杆菌蛋白，以提供有效且廉价的新型抗结核疫苗。
